Loading...
Market
Will CN201 be FDA approved for autoimmune diseases by August 9, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and official Merck press releases
Story
Merck Acquires CN201 B-Cell Therapy for Up to $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance and diversify Merck's pipeline. The drug has potential applications in treating B-cell malignancies and autoimmune diseases. The deal is valued at up to $1.3 billion, reflecting Merck's continued investment in innovative therapies.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
